Devenport M - Search Results

1

Lipid and carbohydrate metabolism in premenopausal women given subdermal estradiol implants.

Crook D, Montgomery JC, Godsland IF, Devenport M, Marenah CB, Studd JW, Wynn V. Crook D, et al. Among authors: devenport m. Horm Metab Res. 1991 Apr;23(4):174-7. doi: 10.1055/s-2007-1003645. Horm Metab Res. 1991. PMID: 1874476

2

Danazol induces resistance to both insulin and glucagon in young women.

Bruce R, Godsland I, Stevenson J, Devenport M, Borth F, Crook D, Ghatei M, Whitehead M, Wynn V. Bruce R, et al. Among authors: devenport m. Clin Sci (Lond). 1992 Feb;82(2):211-7. doi: 10.1042/cs0820211. Clin Sci (Lond). 1992. PMID: 1311660 Clinical Trial.

3

The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. Godsland IF, et al. Among authors: devenport m. N Engl J Med. 1990 Nov 15;323(20):1375-81. doi: 10.1056/NEJM199011153232003. N Engl J Med. 1990. PMID: 2146499 Free article.

4

Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.

Devenport MH, Crook D, Wynn V, Lees LJ. Devenport MH, et al. Br J Clin Pharmacol. 1989 Jun;27(6):851-9. doi: 10.1111/j.1365-2125.1989.tb03449.x. Br J Clin Pharmacol. 1989. PMID: 2547410 Free PMC article. Clinical Trial.

5

Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.

Godsland IF, Crook D, Devenport M, Wynn V. Godsland IF, et al. Among authors: devenport m. Contraception. 1995 Sep;52(3):143-9. doi: 10.1016/0010-7824(95)00153-2. Contraception. 1995. PMID: 7587185

6

Determinants of bone density in normal women: risk factors for future osteoporosis?

Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Stevenson JC, et al. Among authors: devenport m. BMJ. 1989 Apr 8;298(6678):924-8. doi: 10.1136/bmj.298.6678.924. BMJ. 1989. PMID: 2497859 Free PMC article.

7

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.

Magenau J, Jaglowski S, Uberti J, Farag SS, Riwes MM, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang MJ, Burns LJ, Liu Y, Zheng P, Reddy P. Magenau J, et al. Among authors: devenport m. Blood. 2024 Jan 4;143(1):21-31. doi: 10.1182/blood.2023020250. Blood. 2024. PMID: 37647633 Clinical Trial.

8

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy.

Liu M, Wang X, Du X, Wu W, Zhang Y, Zhang P, Ai C, Devenport M, Su J, Muthana MM, Su L, Liu Y, Zheng P. Liu M, et al. Among authors: devenport m. Sci Transl Med. 2023 Mar;15(685):eabm5663. doi: 10.1126/scitranslmed.abm5663. Epub 2023 Mar 1. Sci Transl Med. 2023. PMID: 36857433 Free PMC article.

9

CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.

Wang X, Liu M, Zhang J, Brown NK, Zhang P, Zhang Y, Liu H, Du X, Wu W, Devenport M, Tao W, Mao-Draayer Y, Chen GY, Chen YE, Zheng P, Liu Y. Wang X, et al. Among authors: devenport m. Cell Metab. 2022 Aug 2;34(8):1088-1103.e6. doi: 10.1016/j.cmet.2022.07.005. Cell Metab. 2022. PMID: 35921817 Free PMC article.

10

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect.

Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng P. Liu M, et al. Among authors: devenport m. Signal Transduct Target Ther. 2022 Jul 15;7(1):224. doi: 10.1038/s41392-022-01030-x. Signal Transduct Target Ther. 2022. PMID: 35835736 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters